|About Clinical Trials|
|NCCTG Trial Listings|
|Institutional Members Only|
The North Central Cancer Treatment Group (NCCTG) is a national clinical research group sponsored by the National Cancer Institute. NCCTG consists of a network of cancer specialists at community clinics, hospitals and medical centers in the United States and Canada. The research base for NCCTG is located at Mayo Clinic in Rochester, Minn.
NCCTG is dedicated to bringing clinical trials with promising new cancer therapies to communities where patients live. NCCTG specializes in researching methods of treating and preventing cancer, and in researching methods to alleviate the side effects of cancer and cancer treatments.
The leadership of the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation study (ALTTO) today announced that it will discontinue Arm 2 of the international, phase III clinical trial of two targeted therapies for patients with early stage HER2?positive breast cancer. In this trial all patients received other treatments as part of standard of care (such as chemotherapy, radiation, anti?estrogens) after surgery, and were randomized to one of four different ways to receive the two types of anti?HER2 therapy trastuzumab or lapatinib. The change in status of this trial directly affects patients assigned to Arm 2, those patients receiving lapatinib alone.
This section provides information on National Cancer Institute (NCI) initiatives to restructure the National Cancer Clinical Trials System and updates on NCCTG initiatives to respond to these new directives and collaborate with the Cancer and Leukemia Group B (CALGB) and the American College of Surgeons Oncology Group (ACOSOG) to form a new cooperative group organization. Click here for more details.
200 First Street SW
Rochester, MN 55905
© Copyright 2013, NCCTG